Ornim's blood flow monitor cleared by FDA
This article was originally published in Clinica
Ornim's CerOx 3210F monitor has received 510(k) clearance from the US FDA for a new indication: noninvasive monitoring of tissue blood flow in adults. Previously, it was cleared for noninvasive monitoring of regional haemoglobin oxygen saturation in the brain or skeletal muscle. The device is used in settings including critical care, trauma units, operating rooms and emergency response vehicles. It comprises a stand-alone bedside unit and two sensors that are placed on the skin using an adhesive pad. These employ the firm's patented UTLight technology to measure oxygen saturation using the colour of blood, and blood flow using the phase of light. The oximetry monitoring market is growing by 20% per year, Santa Clarita, California-based Ornim estimates. CerOx 3210F is already CE marked for sale in Europe.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.